Retatrutide research material
Retatrutide is investigated as an agonist of the GIP, GLP-1 and glucagon receptors. This listing is for laboratory research material. It should not be equated with a clinical trial formulation or a finished medicine.
Select a catalog size below to compare current prices and availability. The milligram quantity identifies the listed product size, not a recommended dose or administration instruction.
Research context
Published work by Urva and colleagues examines retatrutide and gastric emptying in a research setting. Read the study record for its methods and limitations. A publication about a compound does not verify the identity, purity or performance of a supplied batch.
Retatrutide: Mechanism & Published Research
Retatrutide (LY3437943) is a long-acting, once-weekly peptide agonist studied for its simultaneous activation of three metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). This triple-agonist profile distinguishes it from dual agonists such as tirzepatide and single-agonist GLP-1 drugs such as semaglutide.
In the published literature, researchers have examined retatrutide’s pharmacokinetic profile extensively. The compound exhibits a plasma half-life in the range of approximately five to seven days in published pharmacokinetic studies, enabling once-weekly research protocols. This extended half-life is attributed to fatty acid side-chain conjugation that promotes albumin binding, a structural feature shared with other long-acting peptide analogs.
Published clinical research on retatrutide is summarized in our retatrutide research review. Researchers studying energy homeostasis have reported that the glucagon receptor component may contribute to increased hepatic glucose output and energy expenditure modulation, effects not observed with GLP-1 mono-agonism alone. The GIP component is thought to potentiate insulin secretion in a glucose-dependent manner and may contribute to improved tolerability relative to GLP-1-only compounds.
Retatrutide has also attracted research interest in the context of non-alcoholic steatohepatitis (NASH) and cardiovascular metabolic disease, with investigators examining biomarkers including alanine aminotransferase, liver fat fraction by MRI-PDFF, and HOMA-IR. It is important to note that retatrutide remains an investigational compound and has not been approved by Health Canada or the FDA for any therapeutic indication.
Research use only: this information is provided for scientific reference. Canada Peptide Supply does not provide medical advice. Retatrutide is not approved by Health Canada for human consumption, diagnosis, treatment, or prevention of disease.
Batch documentation
Before ordering, contact us with the product name and selected size to ask which batch documentation is available. For an existing order, include the batch number on the label. Match any certificate to the exact batch and review the methods and results reported; a purity result alone does not establish sterility or suitability for human use. See our COA policy.
Shipping within Canada
Orders ship within Canada. Standard shipping is $24.99 CAD and express shipping is $49.99 CAD. Free standard shipping applies to a merchandise subtotal of $250 CAD or more; express shipping is not included. Review shipping, dispatch and returns before ordering. Transit estimates begin after dispatch.
Intended use and handling
For laboratory research only. Not for human or veterinary use. Confirm the supplied form, batch specifications, storage requirements and compatibility with your laboratory protocol before purchase. Follow the product label and applicable batch documentation.
Frequently asked about Retatrutide
Is Retatrutide legal in Canada?
Retatrutide is an investigational peptide supplied strictly for in-vitro laboratory research. It is not approved by Health Canada for human use. Researchers are responsible for confirming that their purchase and intended laboratory use comply with applicable Canadian requirements.
What does the published research report?
Published clinical and preclinical research on retatrutide is summarized in our retatrutide research review. We do not provide dosing recommendations for human use.
What is your refund policy?
Refunds, replacements and damaged-order claims follow our shipping, dispatch and returns policy.
Compare Retatrutide options
Select an option in the product selector to view its details and order. Prices and availability may change.
Reviews
There are no reviews yet.